Moreover, derivatives of 2-oxindole (OXIDs) (Figure 4B), have been shown to disrupt the PDK1/Akt pathway and comprise good candidates for non-small cell lung cancer treatment [97], and these results initiated studies for the synthesis and assessment of new derivatives within the same family, which gave rise to promising candidates for the targeting of glioblastoma multiforme (GBM) [98]. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.